Emerging implications of nanotechnology on cancer diagnostics and therapeutics

Cancer

Volumn 107, Issue 3, 2006, Pages 459-466

  Cuenca, Alex G ^a   Jiang, Huabei ^b   Hochwald, Steven N ^a   Delano, Matthew ^a   Cance, William G ^a   Grobmyer, Stephen R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cancer; Carbon nanotubes; Gold nanoparticles; Liposomes; Nanoshells; Nanotechnology; Paramagnetic nanoparticles; Photothermal ablation; Quantum dots; Review

Indexed keywords

CARBON NANOTUBE; COLLOIDAL GOLD; DRUG VEHICLE; GELATIN; GOLD; LIPOSOME; NANOPARTICLE; NANOSHELL; QUANTUM DOT; SOLID LIPID NANOPARTICLE;

CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL PRACTICE; DRUG DELIVERY SYSTEM; HUMAN; MAGNETISM; MICELLE; NANOTECHNOLOGY; NONHUMAN; ONCOLOGY; PARAMAGNETIC NANOPARTICLE; PRIORITY JOURNAL; REVIEW; SCALE UP;

ANIMALS; HUMANS; NANOSTRUCTURES; NANOTECHNOLOGY; NANOTUBES, CARBON; NEOPLASMS;

EID: 33746319850     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22035     Document Type: Review

References (84)

1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:161-171.
2. Exploring nanotechnology and cancer. Available at URL: http://nano.cancer.gov/resource_center/nano_critical.asp.
3. Kaul G, Amiji M. Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. J Drug Target. 2004;12(9-10):585-591.
4. Kaul G, Amiji M. Tumor-targeted gene delivery using poly (ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res. 2005;22:951-961.
5. Cherian AK, Rana AC, Jain SK. Self-assembled carbohydrate-stabilized ceramic nanoparticles for the parenteral delivery of insulin. Drug Dev Ind Pharm. 2000;26:459-463.
6. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003;8:1112-1120.
7. Torchilin VP. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci. 2004;61(19-20):2549-2559.
8. Jain KK. Nanotechnology-based drug delivery for cancer. Technol Cancer Res Treat. 2005;4:407-416.
9. Ibrahim NK, Samuels B, Page R, et al. Multicenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005;23:6019-6026.
10. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803.
11. Damascelli B, Cantu G, Mattavelli F, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer. 2001;92:2592-2602.
12. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005;23:7785-7793.
13. Schellenberger EA, Bogdanov A Jr., Hogemann D, Tait J, Weissleder R, Josephson L. Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Mol Imaging. 2002;1:102-107.
14. Parungo CP, Ohnishi S, De Grand AM, et al. In vivo optical imaging of pleural space drainage to lymph nodes of prognostic significance. Ann Surg Oncol. 2004;11:1085-1092.
15. Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA. 2003;100:13549-13554.
16. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA. 2002;99:12617-12621.
17. Paciotti GF, Myer L, Weinreich D, et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 2004;11:169-183.
18. Wu X, Liu H, Liu J, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semi-conductor quantum dots. Nat Biotechnol. 2003;21:41-46.
19. Nida DL, Rahman MS, Carlson KD, Richards-Kortum R, Follen M. Fluorescent nanocrystals for use in early cervical cancer detection. Gynecol Oncol. 2005;99(3Suppl 1):S89-S94.
20. Wang HZ, Wang HY, Liang RQ, Ruan KC. Detection of tumor marker CA125 in ovarian carcinoma using quantum dots. Acta Biochim Biophys Sin (Shanghai). 2004;36:681-686.
21. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22:969-976.
22. Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat. 2005;4:363-374.
23. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998;95:4607-4612.
24. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol. 2003;3:319-328.
25. Dvorak HF. Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. Prog Clin Biol Res. 1990;354A:317-330.
26. Brigger I, Dubemet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54:631-651.
27. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev. 2003;55:403-419.
28. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145-160.
29. Blume G, Cevc G. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta. 1990;1029:91-97.
30. Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem. 2006;384:620-630.
31. Xu JP, Ji J, Chen WD, Shen JC. Novel biomimetic polymersomes as polymer therapeutics for drug delivery. J Control Release. 2005;107:502-512.
32. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA. 2003;100:6039-6044.
33. Ahmed F, Discher DE. Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. J Control Release. 2004;96:37-53.
34. Huang SL, MacDonald RC. Acoustically active liposomes for drug encapsulation and ultrasound-triggered release. Biochim Biophys Acta. 2004;1665(1-2):134-141.
35. Bruchez M Jr., Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science. 1998;281:2013-2016.
36. Seydel C. Quantum dots get wet. Science. 2003;300:80-81.
37. Alper J. Shining a light on cancer research. NCI Alliance for Nanotechnology in Cancer USA, 2005.
38. Qu L, Peng X. Control of photoluminescence properties of CdSe nanocrystals in growth. J Am Chem Soc. 2002;124:2049-2055.
39. Dubertret B, Skourides R Norris DJ, Noireaux V, Brivanlou AH, Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science. 2002;298:1759-1762.
40. Voura EB, Jaiswal JK, Mattoussi H, Simon SM. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med. 2004;10:993-998.
41. Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol. 2003;7:626-634.
42. Parungo CP, Colson YL, Kim SW, et al. Sentinel lymph node mapping of the pleural space. Chest. 2005;127:1799-1804.
43. Parungo CP, Ohnishi S, Kim SW, et al. Intraoperative identification of esophageal sentinel lymph nodes with near-infrared fluorescence imaging. J Thorac Cardiovasc Surg. 2005;129:844-850.
44. Stroh M, Zimmer JP, Duda DG, et al. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med. 2005;11:678-682.
45. Morgan NY, English S, Chen W, et al. Real time in vivo non-invasive optical imaging using near-infrared fluorescent quantum dots. Acad Radiol. 2005;12:313-323.
46. Derfus AM, Chan WC, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett. 2004;4:11-18.
47. Gao X, Yang L, Petros JA, Marshall FF, Simons JW, Nie S. In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol. 2005;16:63-72.
48. Loo C, Lin A, Hirsch L, et al. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol Cancer Res Treat. 2004;3:33-40.
49. Wang Y, Xie X, Wang X, et al. Photoacoustic tomography of a nanoshell contrast agent in the in vivo rat brain. Nano Lett. 2004;4:1689-1692.
50. Loo C, Lowery A, Halas N, West J, Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 2005;5:709-711.
51. Barton J, Halas NJ, West J, Drezek R. Nanoshells as an optical coherence tomography contrast agent, Tuchin V, Izatt J, Fujifoto J, editors. Proc SPIE. 2004;5316:99-106.
52. Wu C, Liang X, Jiang H. Metal nanoshells as a contrast agent in near infra-red diffuse optical tomography. Opt Commun. 2005;253(1-3):214-221.
53. Sengupta S, Eavarone D, Capila I, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature. 2005;436:568-572.
54. O'Neal DP, Hirsch LR, Halas NJ, Payne JD, West JL. Photothermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett. 2004;209:171-176.
55. Mottram PL. Past, present and future drug treatment for rheumatoid arthritis and systemic lupus erythematosus. Immunol Cell Biol. 2003;81:350-353.
56. Sokolov K, Follen M, Aaron J, et al. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res. 2003;63:1999-2004.
57. Copland JA, Eghtedari M, Popov VL, et al. Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography. Mol Imaging Biol. 2004;6:341-349.
58. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol. 2004;49:N309-N315.
59. Chen J, Saeki F, Wiley BJ, et al. Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. Nano Lett. 2005;5:473-477.
60. Stark DD, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology. 1988;168:297-301.
61. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology. 1990;175:489-493.
62. Michel SC, Keller TM, Frohlich JM, et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology. 2002;225:527-536.
63. Nguyen BC, Stanford W, Thompson BH, et al. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma. J Magn Reson Imaging. 1999;10:468-473.
64. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491-2499.
65. Rockall AG, Sohaib SA, Harisinghani MG, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol. 2005;23:2813-2821.
66. Oyewumi MO, Yokel RA, Jay M, Coakley T, Mumper RJ. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Control Release. 2004;95:613-626.
67. Kobayashi H, Kawamoto S, Sakai Y, et al. Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst. 2004;96:703-708.
68. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med. 2003;49:403-408.
69. Leuschner C, Kumar C, Urbina MO, et al. The use of ligand conjugated supraparamagnetic iron oxide nanoparticles for early detection of metastasis NSTI Nanotechnol. 2005;1:5-6.
70. Winter PM, Caruthers SD, Kassner A, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 Tesla magnetic resonance imaging. Cancer Res. 2003;63:5838-5843.
71. Grimm J, Perez JM, Josephson L, Weissleder R. Novel nanosensors for rapid analysis of telomerase activity. Cancer Res. 2004;64:639-643.
72. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med. 2001;7:1241-1244.
73. Alexiou C, Arnold W, Klein RJ, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000;60:6641-6648.
74. Lubbe AS, Bergemann C, Riess H, et al. Clinical experiences with magnetic drug targeting: a Phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 1996;56:4686-4693.
75. Wisner ER, Katzberg RW, Koblik PD, et al. Iodinated nanoparticles for indirect computed tomography lymphography of the craniocervical and thoracic lymph nodes in normal dogs. Acad Radiol. 1994;1:377-384.
76. Wisner ER, Katzberg RW, Griffey SM, Haley PJ, Johnson DK, Vessey AR. Characterization of normal and cancerous lymph nodes on indirect computed tomography lymphographic studies after interstitial injection of iodinated nanoparticles. Acad Radiol. 1996;3(Suppl 2):S257-S260.
77. Wisner ER, Katzberg RW, Link DP, et al. Indirect computed tomography lymphography using iodinated nanoparticles to detect cancerous lymph nodes in a cutaneous melanoma model. Acad Radiol. 1996;3:40-48.
78. Leander P, Hoglund P, Kloster Y, Borseth A. New liposomal liver-specific contrast agent for CT: first human phase I clinical trial assessing efficacy and safety. Acad Radiol. 1998;5(Suppl 1):S6-S8.
79. Leander P, Hoglund P, Borseth A, Kloster Y, Berg A. A new liposomal liver-specific contrast agent for CT: first human Phase-I clinical trial assessing efficacy and safety. Eur Radiol. 2001:11698-704.
80. Hoglund P, Leander P, Hustvedt SO, Kloster Y, Borseth A. Human pharmacokinetics and modeling of the concentration-attenuation relationship of a new liposomal liver-specific contrast agent for CT. Acad Radiol. 1998;5(Suppl 1):S47-S48.
81. Bianco A, Kostarelos K, Partidos CD, Prato M. Biomedical applications of functionalised carbon nanotubes. Chem Commun (Camb). 2005:571-577.
82. Kam NW, Dai H. Carbon nanotubes as intracellular protein transporters: generality and biological functionality. J Am Chem Soc. 2005;127:6021-6026.
83. Kam NW, O'Connell M, Wisdom JA, Dai H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci USA. 2005;102:11600-111605.
84. Sitharaman B, Kissell KR, Hartman KB, et al. Superparamagnetic gadonanotubes are high-performance MRI contrast agents. Chem Commun (Camb). 2005:3915-3917.